Advances in application of adoptive T-cell therapy for cancer patients.
- Author:
Zou JIXIA
1
;
Zhang CHENGYAN
1
;
Wang PINGLI
2
,
3
Author Information
1. Department of Respiratory Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
2. Department of Respiratory Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China. w_pl77@
3. com.
- Publication Type:Journal Article
- From:
Journal of Zhejiang University. Medical sciences
2017;46(2):211-217
- CountryChina
- Language:Chinese
-
Abstract:
Adoptive T-cell therapy is the administration of tumor cytotoxic T-cells derived from either patient himself or donors, which were induced or genetically engineered and expanded, and then injected into patients. Several strategies for adoptive T-cell therapy have been developed since last 30 years. From lymphokine-activated killer cells, tumor-infiltrating lymphocytes, cytokine-induced killer cells, to gene-modified T-cells and tumor associated antigen (TAA)-specific cytotoxic T-cells, the adoptive T-cell therapy has been moving forward to more precise tumor targeting and more effective in elimination of cancer cells. This article reviewed the advances of therapeutic approaches of adoptive T-cell therapy for cancer patients.
